We have characterized the molecular defect causing androgen resistance in two 46 
Introduction
Mutations in the human androgen receptor (AR)' cause a variety of syndromes of androgen resistance, ranging from women with complete testicular feminization to undervirilized infertile men ( 1) . These disorders have been classified on the basis ofthe level and character ofandrogen binding in cultured genital skin fibroblasts into groups of patients in which no specific binding is detected (receptor binding negative), those with reduced quantities of qualitatively normal receptor binding (receptor binding reduced), those with normal levels of qualita-tively abnormal receptor protein, and a final group with normal levels of qualitatively normal receptor binding (receptor binding positive). The cloning of the cDNA for the AR has permitted the elucidation of the molecular defect in a number of families. Receptor binding negative androgen resistance has been traced to gene deletions (2, 3) , premature termination of the receptor protein (4-7), and amino acid substitutions within the hormone-binding domain (8, 9) . Qualitative abnormalities can be caused by single amino acid replacements in the hormone-binding domain ( 10, 11 ) , and receptor binding positive androgen resistance is frequently due to amino acid substitutions in the DNA-binding domain ( 12, 13 ).
In the current work we report the analysis ofthe AR gene in two siblings with complete testicular feminization and a diminished amount of qualitatively abnormal AR. The elucidation of this mutation permitted the antenatal analysis of the AR gene in a fetus at risk.
Methods
Clinical summary. Subject R776 was identified at birth as a female with bilateral inguinal testes. Subsequent evaluation revealed the presence of testes in the hernia, a 46,XY karyotype, and the phenotype of testicular feminization. Her younger sister (R782) had a normal female phenotype at birth but was found on further evaluation to have a 46,XY karyotype ( Fig. 1 A) . The dihydrotestosterone binding capacities (Bmax) in fibroblast monolayers cultured from biopsies of labia majora were 7 and 10 fmol/mg protein for subjects R776 and R782, respectively (Table I) .
After the mutation responsible for androgen resistance in this family was defined, the mother of the propositus became pregnant. As she wished to ascertain whether she was carrying an affected fetus, amniocentesis and chorionic villus sampling were performed at week 8, and a portion of this sample was used to grow primary cultures of amniotic fluid cells. Fetal DNA was prepared directly from the chorionic villus sample and from confluent culture of villus cells. Sequence analysis of the fetal AR gene was carried out as described below.
DNA preparations and AR gene analysis. Confluent monolayers of fibroblasts were scraped into ice-cold PBS, pelleted, and processed as described (4) . All eight coding exons ofthe human AR gene are present and grossly intact in patients R776 and R782 (data not shown). Amplification and sequence analysis of the human AR was performed by polymerase chain reaction amplification and dideoxy sequencing of the coding exons as before (5) . The sequence of the GGC repeats in exon 1 was not determined.
Immunoblots. Immunoblots were performed as described by Wilson et al. ( 14) . In brief, genital skin fibroblasts from subjects R776 and R782 and from a normal control (704) were homogenized in SDS-PAGE loading buffer and centrifuged for 30 min at 200,000 g. Aliquots of the supernatant fraction, termed cell extract, were applied to a 7.5% acrylamide gel containing 3.5 nM sodium dodecyl sulfate, separated by electrophoresis, transferred to nitrocellulose, and incubated sequentially with affinity-purified polyclonal antibodies and with '251I-labeled Cell culture and transfection. Chinese hamster ovary (CHO), CV 1, and COS cell lines from the American Type Culture Collection (Rockville, MD) were maintained as described (5, 9, 13) . Transfections were performed by using the calcium phosphate precipitation method (16) as before (5 and 41°C for 1 h. After incubation the cells were harvested and processed as above ( 19) . The rate of ligand dissociation was examined by preincubating parallel cultures with 2 nM [3H]mibolerone for 1 h at 37'C in the presence or absence of excess unlabeled mibolerone. At time 0 the medium containing radioactive ligand was removed and replaced with medium containing 2 nM cold mibolerone, and the incubation was continued for 5 h. The amount ofspecific radioactive mibolerone remaining at hourly intervals was compared with the level of binding in samples to which no competitor steroid had been added ( 19) . Sucrose density gradient centrifugation analysis of labeled cytosol from fibroblasts was performed in TEGM-l0 buffer (50 mM TrisHCl, 1 mM EDTA, 10% [vol/vol] glycerol, 1 mM 2-mercaptoethanol, and 10 mM sodium molybdate, pH 7.4) as described previously ( 19) .
Analysis oftransactivation activity. CV 1 cells were used in transient transfection experiments to examine the effect of the mutation on the transactivation activity of the receptor (5). Transfections were performed by the calcium phosphate precipitation method with plasmids encoding normal or mutant AR, the reporter plasmid MMTV-CAT, and a control plasmid, CMV-,B-galactosidase. After transfection the cells were incubated in medium containing 5% charcoal-stripped serum in the presence or absence of 2 nM dihydrotestosterone. After 48 h the cells were harvested and assayed for chloramphenicol acetyl transferase (CAT) (20) and f-galactosidase activity (21) . In these experiments the level of CAT activity reflects the transactivation activity of the different ARs, and 3-galactosidase activity is assessed to correct for the efficiency of transfection.
COS cells were transiently transfected by the calcium phosphate precipitation method with normal or mutant AR plasmids and with the control plasmid CMV-3-galactosidase. Extracts from these cells were used in immunoblot analysis and to assay 0-galactosidase activity.
Results
Fibroblasts from subjects R776 and R782 express a reduced amount ofqualitatively abnormal AR in binding assays. Genital skin fibroblasts established from subjects R776 and R782 consistently demonstrated a low but detectable level of specific androgen binding. Although this level varied somewhat from assay to assay, the amount averaged -8 fmol / mg protein (range 5-10). Ligand binding was stable at elevated temperature but exhibited an accelerated ligand dissociation rate (Table I). Sucrose density gradient analysis of ligand-receptor complexes containing AR from strain R776 prepared in low ionic strength buffer revealed a sedimentation profile similar to that obtained with normal AR (data not shown).
Anti-NH2-terminal antibodies do not detect androgen receptor in immunoblots offibroblast strain R 776 and R 782. The level of immunoreactive AR in fibroblasts was assessed with antibodies (U402) that recognize the amino terminus of the receptor protein (15) . As shown in Fig. 3 Figure 3 . Absence of immunoreactive AR in immunoblots of cell extracts prepared from genital skin fibroblasts of subjects R776 and R782. The indicated quantities of cell extract were fractionated by electrophoresis on a 7.5% SDS polyacrylamide gel, transferred to nitrocellulose, and probed with antibodies directed at the NH2 terminus of the AR. The control (strain 704) shows a major 1 I 0-kD immunoreactive band. No immunoreactive AR band is detected in fibroblasts established from subjects R776 or R782.
version of a codon (CAG) encoding glutamine 60 into a termination codon (TAG). The remainder of the AR gene carried by these two individuals is otherwise normal except for minor differences in the lengths of glutamine homopolymeric segment. The size of the glycine homopolymeric region was not determined. These changes are shown schematically in Fig. 1 B. Although we demonstrated that the same mutation is present in subject R782, the mutant gene is referred to as that predicted for subject R776 and the mutation is denoted as Q60X in the remainder of this manuscript.
Consequences of termination of the receptor protein at amino acid 60. The premature termination codon in exon 1 would be expected to cause the termination of the receptor protein at amino acid residue 60. The presence of specific ligand binding despite the presence ofthe premature stop codon suggested that initiation oftranslation must occur at a point on the AR mRNA 3' to the premature termination codon.
To examine the effects ofthis mutation in detail, the C-*T nucleotide substitution was inserted into an AR cDNA in the eukaryotic expression vector CMV3. This expression plasmid (CMV776) or an expression plasmid encoding the normal AR (CMV3. 1 ) were transfected into CHO cells using the selectable marker pSV2neo and analyzed for the presence and quantity of specific androgen binding. As shown in Table I , the receptor binding in cells stably transfected with the CMV776 plasmid has similar characteristics to that of the AR in fibroblasts cultured from the patient, as evidenced by a normal apparent Kd and an increased dissociation rate. These findings support the possibility that a truncated AR protein is synthesized by initiation at a downstream initiator methionine and that this mutant receptor is capable of binding hormone with normal affinity.
The mutant AR predictedfor subject R776 can activate an androgen-responsive reporter gene. To assess the capacity ofthe truncated AR protein for gene activation, cDNAs encoding the normal and mutant ARs were cotransfected into recipient cells with a reporter plasmid, mouse mammary tumor virus (MMTV)-CAT. After incubation with ligand, the level oftransactivation of the reporter gene was assayed by comparing the basal and stimulated levels of CAT activity achieved by the proteins encoded by the normal and mutant AR cDNAs (Fig.  4) (Fig. 6 A) or with antibodies to the NH2 terminus (data not shown). Anti-internal A peptide antibodies also react with the 1 10 kD full-length AR protein in these samples but produce a different pattern of smaller immunoreactive proteins (Fig. 6 B) . As expected, no 1 (Fig. 6 A) , or the internal A sequence (Fig. 6 B) . However, anti-COOH-terminus antibodies and antiinternal A antibodies both react with an -87-kD protein that is present in these samples but not in untransfected COS cells or COS cells transfected with CMV3.1 ( Fig. 6 A During the course of these studies, the proband's mother became pregnant and wished to ascertain whether she was carrying an affected fetus. For this reason, amniocentesis and chorionic villus sampling were performed at week 8. After karyotype analysis revealed a 46,XY genotype, DNA was prepared from both biopsied chorionic villi and cultured amniotic fluid cells. Samples derived from four separate amplifications were subjected to nucleotide sequence analysis and found to reveal a normal AR gene sequence at amino acid position 60. The expectation of normal male sexual development was confirmed by the detection of a phallus by ultrasonography at week 16 and by the presence ofa normal male phenotype of the infant at birth.
Discussion
The present work was undertaken to define the molecular defect causing androgen resistance in two siblings with complete testicular feminization associated with reduced but demonstra- Although COS cells transfected with R776 mutant cDNA synthesize the mutant AR protein, the truncated receptor accumulates to a level that is at least 100-fold less than in cells transfected with the cDNA encoding the normal AR. There are at least two possible mechanisms for reduced level of expression. First, although the sequences surrounding the ATG at amino acid 188 suggest that it can be used as an initiator methionine (22, 23 ), the process oftranslation from internal methionines may be inefficient (24) . Second, the steady state level of AR mRNA may also be decreased, as has been demonstrated in other subjects with premature termination codons in the AR gene (5, 9 The AR, like several other members of the steroid receptor family, contains a transactivation domain in the NH2-terminal region. This domain was located between amino acid residues 141 and 338 by Simental et al. (25) and between amino acid 51 and 360 by Jentsen et al. (26) . In their experiments, performed by inducing artificial deletions within the coding sequence of the human AR, removal ofthese two segments was followed by complete loss of transcriptional activity. The AR predicted for subjects R776 and R782 would lack 187 amino acids at the amino terminus of the receptor. The transactivation capacity of this receptor is markedly reduced when the assay is performed under standard circumstances (200 ng of mutant AR expression plasmid cotransfected with 10 gg of the MMTV-CAT reporter plasmid). On the other hand, by transfecting increasing amounts of plasmid CMV-776, we were able to induce a substantial increase in the level oftransactivation ofthe reporter gene, up to 30% of the normal control. These findings suggest that the first 187 amino acids are required for normal AR function. These results also imply that the regions deleted by Simental et al. (25) and Jentsen et al. (26) that resulted in a complete loss of receptor function may lie between amino acid residues 188 and 338 or 360.
No previous mutation within the amino terminus of the AR has been reported to cause androgen resistance in humans, although in one patient with a qualitative abnormality of androgen binding, a truncation within the amino terminal glutamine homopolymeric segment accentuated the effect of an amino acid substitution in the hormone-binding domain ofthe receptor protein ( 11) . Three groups have reported that androgen resistance in the Tfm mouse is caused by a frame shift at amino acid position 371 followed by a premature termination of the AR protein occurring 42 amino acids later (27) (28) (29) . Those studies suggested that reinitiation of AR protein synthesis at a methionine downstream of the premature stop codon might account for residual [3H ]dihydrotestosterone binding found in the Tfm mouse. The current work documents that such a phenomenon can occur in cells and suggests that a combination ofdiminished receptor abundance and function cause the clinical phenotype.
As noted previously, studies of ligand binding in genital skin fibroblast cultures have defined categories of androgen resistance on the basis ofqualitative and quantitative abnormalities ofthe AR protein ( 1 ) . Studies in several laboratories have shown that the mechanisms responsible for receptor-binding negative androgen resistance encompass a broad spectrum of genetic abnormalities, including gene deletions, premature termination codons, amino acid substitutions, and alterations of the AR mRNA splicing. In contrast, the mechanisms causing receptor-binding positive androgen resistance are more homogeneous and result from single amino acid substitutions in the DNA-binding domain of the receptor protein.
The present paper describes the molecular characterization oftwo subjects with both qualitative and quantitative defects in androgen binding. Two mechanisms cause the androgen resistance in these subjects: reduction of the level of AR expression due to premature termination and inefficient initiation of translation at an internal methionine and diminished transactivation capacity of the truncated AR molecules that result. These findings have several implications. First, they demonstrate that alterations within the amino terminus ofthe human AR gene that do not change the structure of the DNA-and hormone-binding domains can cause complete androgen resistance. Second, these studies suggest that regions of the amino terminus of the AR demonstrated to be important for receptor function using in vitro assays (25, 26) are required for in vivo function. Third, it is evident from the current work that substantial alterations within the structure ofamino terminus may result in only minor binding abnormalities. Studies of additional patients with complete or partial forms ofandrogen resistance and with subtle abnormalities of receptor binding will be necessary to determine what proportion is due to alterations within the amino terminus of the receptor.
